A rare case of primary synovial sarcoma localized in the thoracic inlet

Sezen, Celal Buğra; Gülgösteren, Mahmut; Memış, Leyla; Taştepe, Abdullah İrfan

doi:10.26663/cts.2019.00019

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulmonary carcinosarcomas are poorly differentiated biphasic tumors with epithelial and mesenchymal components. These tumors are rare and are considered to form a subgroup of pulmonary sarcomatoid carcinomas [10][11][12]. PPCs commonly present in men with smoking histories.…”

Section: Discussionmentioning

confidence: 99%

Primary pulmonary carcinosarcomas: postoperative results and survival analysis

Doğru¹,

Sezen²,

Aker³

et al. 2020

Curr Thorac Surg

Self Cite

View full text Add to dashboard Cite

Background: In this study, we assessed the long-term results of 11 patients that we operated due to primary pulmonary carcinosarcoma in the light of literature. Materials and Methods: We analyzed 11 patients' data, who underwent lung resection, retrospectively between 2009-2018. The comorbidity score was calculated according to the modified Charlson Comorbidity Index (CCI). Results: Of the 11 patients in the study, 10 (90.9%) were male, one was female (%9.1), and the median age of the subjects was 59.18 ± 8.86. Nine of the patients (81.8%) underwent lobectomy, two of them (18.1%) underwent pneumonectomy. As a cellular type, 6 of them have squamous cell carcinoma, 5 of them have adenocarcinoma. Furthermore, as a sarcomatous component, we detected 6 of the patients have spindle cell sarcoma, 3 of them have chondrosarcoma, one of them has osteosarcoma. and one patient has angiosarcoma. Nine complications occur postoperatively in 5 patients (45.9%). The fiveyear survival rate was 36.4%. Patients who received adjuvant chemotherapy, the five-year survival rate was 50%, meanwhile, patients who did not receive adjuvant chemotherapy five-year survival rate was not detected (P = 0.006). If the patients have CCI score is two and below their five-year survival rate was 44.4%, meanwhile if the patients have CCI score is two and above their five-year survival rate was not detected (P = 0.018). Recurrence or metastasis was diagnosed in 7 patients (63.6%) postoperatively. The 5-year disease-free survival rate is 12.5%. Conclusions: Surgical resection is still the most effective treatment modality for these patients. Adjuvant therapy and comorbidity are detected most important factors that affect the survival rate.

show abstract

Section: Discussionmentioning

confidence: 99%